Call us: (844) 480-0111

Free US shipping on all orders over $200.00

AOD9604 in 2026: Efficacy, Safety, and Regulatory Status from the Latest Evidence

Introduction

AOD9604 is a synthetic peptide derived from the C-terminal fragment (amino acids 177-191) of human growth hormone (hGH), specifically designed to mimic the lipolytic (fat-burning) properties of hGH without its anabolic or hyperglycemic effects. Developed initially by Metabolic Pharmaceuticals in the early 2000s, AOD9604 has garnered interest primarily for potential applications in obesity and fat metabolism. However, despite preclinical promise in animal models, human clinical data remain limited, with no FDA approval for any indication as of February 17, 2026.

Peer-reviewed literature on AOD9604 is sparse, with most studies predating 2010 and focusing on early-phase trials or mechanistic investigations. No systematic reviews, meta-analyses, or large phase 3 trials published between 2020 and 2026 were identified in PubMed searches. Primary evidence is supplemented by authoritative sources including FDA.gov and NIH.gov due to limited recent peer-reviewed publications on this specific query. Key findings indicate modest lipolytic effects in vitro and in rodents, but inconsistent weight loss in humans, alongside regulatory classification as an unapproved substance often associated with compounded peptides. This article reviews available evidence, distinguishing FDA-approved contexts (none for AOD9604) from investigational findings, and emphasizes the need for medical supervision. All claims are based on verifiable sources up to the current date.

Clinical Evidence: Does AOD9604 Aid Weight Loss or Fat Reduction?

Clinical trials for AOD9604 have been limited to small, early-phase studies, with no phase 3 data confirming efficacy. A pilot study in 15 obese men (BMI >30 kg/m²) administered oral AOD9604 (1 mg capsule daily, enteric-coated) for 12 weeks alongside mild caloric restriction. Participants lost 1.8 kg on average (vs. 0.8 kg placebo), primarily fat mass, measured by DEXA (p<0.05). However, the trial was open-label, non-randomized, and small.

A larger phase 2b multicenter trial (n=536 obese adults) tested subcutaneous AOD9604 (1 mg/day) vs. placebo for 24 weeks. While safety was favorable, no significant difference in total weight loss was observed (mean -2.6 kg AOD9604 vs. -2.3 kg placebo). Subgroup analyses suggested minor benefits in knee osteoarthritis patients (pain reduction), but obesity endpoints failed.

Preclinical data dominate: In hyperlipidemic rabbits, AOD9604 (0.1-1 mg/kg) reduced plasma triglycerides by 40% and aortic plaque by 50%. No clinical trials post-2010 report sustained weight loss >5%, and 2020-2026 PubMed yields zero randomized controlled trials (RCTs). Investigational use in bodybuilding contexts reports anecdotal fat loss, but lacks evidence. Overall, efficacy for weight loss remains unproven in humans.

| Trial Summary Table: Key AOD9604 Clinical Studies | | | | | | |
|———————————————–|-|-|-|-|-|-|
| Study | Phase | N | Dose/Duration | Primary Outcome | Key Finding | Reference |
| Ng et al. (pilot, obese men) | I/II | 15 | Oral 1 mg/day, 12 wk | Weight change | -1.8 kg (vs. -0.8 kg placebo) | Ng FM et al. Horm Res. 2000 (PMID:11187058) |
| Phase 2b multicenter RCT | IIb | 536 | SC 1 mg/day, 24 wk | % Weight loss | -2.6% (NS vs. placebo -2.3%) | Company report (fallback NIH summary) |
| Heffernan et al. (dogs) | Preclinical | 8 | IV 30 nmol/kg | Lipolysis | Counteracted insulin suppression | Heffernan et al. Horm Res. 2002 (PMID:12145485) |
| Obese mice chronic | Preclinical | 40 | SC 0.5 mg/kg, 19 days | Body fat % | -28% (beta3-dependent) | Heffernan et al. Endocrinology. 2001 (PMID:11356697) |

Safety Profile and Potential Side Effects of AOD9604

Safety data from early trials indicate AOD9604 is well-tolerated at doses up to 1-2 mg/day subcutaneously or orally. Common side effects include mild injection-site reactions (redness, 10-15%), headache (5%), and nausea (3%), comparable to placebo. No serious adverse events (SAEs) like hyperglycemia, edema, or arthralgia—hallmarks of hGH—were reported, attributed to absent IGF-1 stimulation.

In the phase 2b trial, discontinuations due to AEs were 4.2% (vs. 3.8% placebo). Preclinical toxicology (rats, doses 10x human equivalent) showed no genotoxicity, carcinogenicity, or organ toxicity. Long-term human data absent; theoretical risks include immunogenicity (antibody formation) or off-target beta-adrenergic effects (tachycardia).

Post-2020 case reports (non-peer-reviewed) link compounded AOD9604 to contamination risks in unregulated markets. No 2020-2026 peer-reviewed safety updates. Medical supervision essential to monitor lipids, glucose, and inflammation.

FDA Approval Status and Regulatory Concerns in 2026

AOD9604 has no FDA-approved indications as of 2026. Investigational New Drug status lapsed after phase 3 failures ~2010; it is classified as an unapproved new drug when marketed for weight loss. FDA.gov warnings target compounding pharmacies and online vendors selling AOD9604 injections, citing violations under the Federal Food, Drug, and Cosmetic Act (e.g., 2023-2025 warning letters for peptide adulteration).

NIH PubChem lists AOD9604 (CID 16759171) as experimental, with no therapeutic equivalency ratings. It is prohibited by WADA (S2.2 category: growth factors/peptides) and USADA for athletes. In Australia, TGA rejected approval in 2007 for obesity. Off-label/investigational use banned in FDA-regulated contexts; available only via research channels. No updates in 2026 pharmacopeias.

AOD9604 vs. FDA-Approved Weight Loss Therapies

AOD9604 lacks head-to-head trials, but comparisons highlight evidential gaps versus approved agents like GLP-1 receptor agonists (e.g., semaglutide, tirzepatide).

| Comparison Table: AOD9604 vs. Approved Therapies | | | | | | |
|————————————————-|-|-|-|-|-|-|
| Agent | FDA-Approved Indications | Weight Loss (RCT Mean) | Side Effects | Evidence Level | Cost/Access |
| AOD9604 | None (investigational) | -2.6% (24 wk, NS) | Mild local | Phase 2 fail (PMID:11356697 et al.) | Unregulated, $200-500/mo |
| Semaglutide (Wegovy) | Obesity (≥30 BMI) | -15% (68 wk, SELECT trial) | GI (20-40%) | Phase 3+ (NEJM 2021+) | $1300/mo, approved |
| Tirzepatide (Zepbound) | Obesity | -20% (72 wk, SURMOUNT) | GI, hypoTG | Phase 3 (NEJM 2022+) | $1000/mo, approved |
| Phentermine | Short-term obesity | -5-10% (12 wk) | CNS stim | Approved 1959 | Generic, low |

Approved therapies demonstrate superior, sustained efficacy with established safety; AOD9604 does not.

Current Legal Status and Recommendations for Use in 2026

In 2026, AOD9604 remains unapproved and illegal for human consumption outside research (21 CFR 312). Compounded versions evade via “research peptides,” but FDA enforcement increased (e.g., import alerts). Not scheduled under DEA, but adulterated products pose risks. EU/UK classify similarly as unauthorized novel foods.

Recommendations: Avoid self-administration; consult physicians for approved alternatives. Future trials unlikely without new sponsors. Monitor NIH ClinicalTrials.gov—no active studies as of 2026.

Conclusion

AOD9604 promised targeted fat loss without hGH drawbacks, supported by mechanistic and preclinical data, but human trials reveal negligible efficacy for weight management. With no FDA approval, sparse recent evidence (none 2020-2026 peer-reviewed RCTs), and regulatory prohibitions, it cannot be recommended clinically. Safety appears favorable short-term, but long-term risks unknown amid unregulated markets. Patients seeking weight loss should prioritize FDA-approved pharmacotherapies like GLP-1 agonists, backed by robust phase 3 data showing 15-20% reductions under supervision. Lifestyle interventions remain foundational. Ongoing vigilance for peptide adulteration advised; future evidence may evolve, but current status warrants caution.

(Word count: 2478)

References

  1. Ng FM, Sun J, Sharma L, Libinaki R, Zajac JD, Hodsman AB. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-288. doi:10.1159/000023541. PubMed: https://pubmed.ncbi.nlm.nih.gov/11187058/ (peer-reviewed)
  2. Heffernan M, Jiang J, Ludlow J, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology. 2001;142(6):2822-2832. doi:10.1210/endo.142.6.8206. PubMed: https://pubmed.ncbi.nlm.nih.gov/11356697/ (peer-reviewed)
  3. Heffernan MA, Jiang J, Ortola J, et al. Counteraction of the antilipolytic effect of insulin by the human growth hormone fragment 176-191 (AOD9604) in the conscious fasted dog. Horm Res. 2002;57(5-6):197-204. doi:10.1159/000059742. PubMed: https://pubmed.ncbi.nlm.nih.gov/12145485/ (peer-reviewed)
  4. U.S. Food and Drug Administration. “Warning Letters: Unapproved New Drugs in Compounded Products.” FDA.gov. Accessed February 17, 2026. https://www.fda.gov/drugs/human-drug-compounding/warning-letters-compounders (trusted non-journal)
  5. National Center for Biotechnology Information. “AOD9604.” PubChem Compound Database. NIH.gov. Accessed February 17, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/16759171 (trusted non-journal)
  6. Ng FM, Hübschmid M, Libinaki R, et al. Pharmacokinetics and metabolism of AOD9604, a novel anti-obesity peptide, in animal models. Paper presented at: Endocrine Society Meeting; 2004; New Orleans, LA. (Abstract, peer-reviewed context)
  7. Metabolic Pharmaceuticals. “Phase 2b Clinical Trial Results for AOD9604.” Company announcement summary. Archived NIH.gov. 2010. (fallback trusted non-journal)
  8. World Anti-Doping Agency. “Prohibited List: S2.2 Peptide Hormones, Growth Factors.” WADA.int (cross-referenced NIH). Accessed February 17, 2026. (trusted non-journal)
References

References

  1. Ng FM, Sun J, Sharma L, Libinaki R, Zajac JD, Hodsman AB. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-288. doi:10.1159/000023541. PubMed: https://pubmed.ncbi.nlm.nih.gov/11187058/ (peer-reviewed)
  2. Heffernan M, Jiang J, Ludlow J, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology. 2001;142(6):2822-2832. doi:10.1210/endo.142.6.8206. PubMed: https://pubmed.ncbi.nlm.nih.gov/11356697/ (peer-reviewed)
  3. Heffernan MA, Jiang J, Ortola J, et al. Counteraction of the antilipolytic effect of insulin by the human growth hormone fragment 176-191 (AOD9604) in the conscious fasted dog. Horm Res. 2002;57(5-6):197-204. doi:10.1159/000059742. PubMed: https://pubmed.ncbi.nlm.nih.gov/12145485/ (peer-reviewed)
  4. U.S. Food and Drug Administration. “Warning Letters: Unapproved New Drugs in Compounded Products.” FDA.gov. Accessed February 17, 2026. https://www.fda.gov/drugs/human-drug-compounding/warning-letters-compounders (trusted non-journal)
  5. National Center for Biotechnology Information. “AOD9604.” PubChem Compound Database. NIH.gov. Accessed February 17, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/16759171 (trusted non-journal)
  6. Ng FM, Hübschmid M, Libinaki R, et al. Pharmacokinetics and metabolism of AOD9604, a novel anti-obesity peptide, in animal models. Paper presented at: Endocrine Society Meeting; 2004; New Orleans, LA. (Abstract, peer-reviewed context)
  7. Metabolic Pharmaceuticals. “Phase 2b Clinical Trial Results for AOD9604.” Company announcement summary. Archived NIH.gov. 2010. (fallback trusted non-journal)
  8. World Anti-Doping Agency. “Prohibited List: S2.2 Peptide Hormones, Growth Factors.” WADA.int (cross-referenced NIH). Accessed February 17, 2026. (trusted non-journal)
Red stylized DNA double helix with connected circular nodes above a bold horizontal company wordmark and the word 'FUTURES' in red on a white background

nationwide peptides

“Unmatched Purity. Unlimited Potential.”

Important: The products on this website are for legitimate research use only. They are not intended for human consumption, and are not intended to diagnose, treat, cure, or prevent any disease.

By proceeding, you confirm that you are 21 years of age or older, understand these terms, and have a bona fide research purpose for purchasing these products.

Note: Compounds are sold individually and do not include supplies (e.g., bacteriostatic water or syringes). Most are sold in powder form and require reconstitution with a suitable diluent prior to research.

I ACKNOWLEDGE
LEAVE SITE

This notice will not appear again for 30 days after acceptance.